The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax®

by Ganguly, Bishu, Balasa, Balaji, Efros, Lyubov, Hinton, Paul R., Hartman, Stephen, Thakur, Archana, Xiong, Joanna M., Schmidt, Brian, Robinson, Randy R., Sornasse, Thierry, Vexler, Vladimir, Sheridan, James P.
Published 2016